What is GPT-Rosalind?
GPT-Rosalind is OpenAI’s specialized reasoning model for life sciences research. It is designed for biology, drug discovery, medicinal chemistry, genomics, protein engineering, and translational medicine rather than general-purpose chat alone.
In practical terms, the model is intended to help researchers work through multi-step scientific questions. Examples include comparing evidence across papers, interpreting genomic or molecular data, examining protein and sequence information, investigating possible drug candidates, troubleshooting wet-lab protocols, and planning experiments that still require review and approval by human experts.
The public model name is GPT-Rosalind. The current API identifier is gpt-rosalind-research. OpenAI describes the API as a rolling GPT-Rosalind model line, meaning eligible organizations receive access to the latest Rosalind models as they are released rather than necessarily working with one permanently fixed version.
Provider, availability, and access
GPT-Rosalind is provided by OpenAI. OpenAI introduced it on April 16, 2026, and describes it as a life sciences research offering rather than an openly available consumer chatbot or a general-purpose API model.
As of September 23, 2026, eligible organizations can request access globally through OpenAI’s trusted-access program. Access is limited to approved internal life sciences research and is subject to organizational review, governance requirements, security controls, and applicable safety conditions. This restriction is important: the model is not positioned as a freely available tool for public experimentation, customer-facing applications, or unsupervised laboratory work.
Its place in OpenAI’s lineup is therefore specialized. Models such as GPT-5.5 are general-purpose systems, while GPT-Rosalind is aimed at organizations that need deeper support for biological and chemical research workflows. OpenAI reports that GPT-Rosalind outperformed GPT-5.5 on several life sciences evaluations, but those comparisons should be understood as provider-reported evaluation results, not a guarantee of performance on every research task.
What GPT-Rosalind can help with
GPT-Rosalind is designed for advanced scientific reasoning across connected areas of life sciences. Its main capabilities include:
- Drug discovery: reasoning about targets, candidate molecules, lead optimization, potency, toxicity, ADME considerations, and retrosynthesis.
- Medicinal chemistry: examining structure-activity relationships and helping researchers compare chemical changes against expected biological effects.
- Genomics and quantitative biology: supporting functional genomics, spatial transcriptomics, proteomics, epigenomics, sequencing analysis, and applied genetics workflows.
- Protein and sequence analysis: working with protein information, sequences, structures, and biological relationships.
- Literature and evidence synthesis: bringing together findings from scientific publications, databases, experimental records, and internal research context.
- Wet-lab support: helping troubleshoot protocols, identify possible causes of failed results, and plan experimental variations.
- Translational research: connecting biological findings with disease-related questions and potential therapeutic development.
These are research-assistance capabilities, not autonomous scientific validation. GPT-Rosalind can propose interpretations or next steps, but researchers must verify sources, inspect data quality, check assumptions, and approve any experiment or consequential decision.
Scientific tools and connected workflows
GPT-Rosalind can be used with OpenAI’s Life Sciences Research and Life Sciences NGS Analysis plugins in Codex. These connected tools can provide access to scientific databases, literature sources, multi-omics resources, sequence and structure viewers, and repeatable analysis workflows.
Documented example workflows include sequence searches, protein-structure lookup, literature review, single-cell RNA sequencing quality control, and bulk RNA sequencing quality control. Tool access can make the model more useful than a text-only system because it can work against research sources and analysis environments rather than relying only on information contained in a conversation.
However, tool use should not be confused with independent laboratory capability. The model does not thereby perform physical experiments, guarantee that a database result is correct, or validate a proposed protocol. Organizations using it should apply identity management, monitoring, least-privilege permissions, source review, and domain-specific governance.
Reasoning performance and evaluations
OpenAI reports that GPT-Rosalind outperformed GPT-5.5 on several life sciences evaluations while using fewer tokens in some comparisons:
| Evaluation | GPT-Rosalind | GPT-5.5 |
|---|---|---|
| MedChemBench | 27.5% | 25.1% |
| GeneBench | 21.6% accuracy | 20.4% accuracy |
| LabWorkBench | 63.2% | 55.8% |
OpenAI’s deployment safety evaluation identifies GPT-Rosalind-5.5 as having high capability in biological and chemical domains while remaining below the critical capability threshold used in that assessment. These are provider claims based on specific evaluations and safety methodology. They should not be interpreted as evidence that the model is consistently correct, safe for unsupervised use, or better than every alternative in every biological task.
For users, the practical distinction is that GPT-Rosalind’s value lies in multi-step scientific reasoning and evidence integration, not simply in producing fluent answers. It may be particularly useful when a task requires relating molecules, proteins, genes, pathways, disease biology, and experimental context.
Input, output, and technical support
The supplied specifications identify text input and text output, with image input supported. GPT-Rosalind does not directly generate images, audio, video, or other non-text media. Image input may be useful for certain scientific materials, but the research does not document the full range of supported image formats or every visual analysis workflow.
| Capability | Available or documented status |
|---|---|
| Text input | Supported |
| Image input | Supported |
| Text output | Supported |
| Image, audio, video, or music output | Not supported |
| Tool use | Supported through connected scientific workflows |
| Streaming | Not publicly documented for the rolling API identity |
| Fine-tuning | Not publicly documented |
| JSON mode and structured output | Not publicly documented |
| Batch API | Not publicly documented |
OpenAI has not publicly documented a context-window limit, maximum output-token limit, knowledge cutoff, or fine-tuning availability for the exact rolling gpt-rosalind-research identity. Users should confirm these details during access provisioning rather than infer them from GPT-5.5 or from the GPT-Rosalind-5.5 system card.
GPT-Rosalind pricing
OpenAI lists standard API pricing at $5 per million input tokens, $0.50 per million cached input tokens, and $25 per million output tokens. Billing is scheduled to begin on October 5, 2026. Cache-write pricing does not apply to this model.
Input tokens represent the text and other processed request content sent to the model, while output tokens represent the generated response. The output price is substantially higher than the input price, so long research responses, repeated analysis, and large generated reports can materially affect costs. Caching may reduce the price of repeated input context where the deployment supports and applies cached inputs.
These are usage prices, not a general subscription price. Access also depends on approval through the trusted-access program, so paying for API usage alone does not imply that an organization can use the model.
Limitations and risks
GPT-Rosalind should not replace laboratory expertise, clinical judgment, regulatory review, or independent biosecurity controls. A plausible explanation of a biological mechanism can still be wrong, incomplete, based on weak evidence, or unsuitable for a particular experimental system.
The model’s specialized focus also creates trade-offs. It is not intended as an open public chatbot, an inexpensive general-purpose assistant, or an autonomous laboratory operator. Organizations must establish controls for sensitive data, research access, tool permissions, monitoring, and review of generated recommendations.
The absence of publicly documented context and output limits is another practical limitation. Teams planning large literature reviews, long experimental records, or structured production pipelines should verify these limits with OpenAI before designing workflows around them. The same applies to streaming, fine-tuning, JSON mode, structured outputs, and Batch API support.
When to choose GPT-Rosalind
GPT-Rosalind is a strong candidate when an approved life sciences organization needs a reasoning-focused model for biology or chemistry work and can support the required governance. It is especially relevant for:
- Drug-discovery teams comparing targets, compounds, mechanisms, or optimization strategies.
- Genomics groups analyzing sequencing and multi-omics workflows.
- Protein researchers working with sequences, structures, and related evidence.
- Scientific teams that need literature synthesis connected to databases or internal research systems.
- Researchers troubleshooting protocols or planning experiments with expert review.
- Organizations that value domain-specific reasoning more than the lowest possible token cost or fastest response time.
Another option may be more appropriate when the task is ordinary writing, broad coding, customer support, low-cost high-volume generation, or an application that requires publicly available access. A general model such as GPT-5.5 may be easier to deploy for broad workloads, while a lower-cost or faster model may be preferable for routine classification and simple extraction. Conversely, GPT-Rosalind is more appropriate when biological and chemical reasoning, scientific evidence integration, and governed tool use justify its higher output cost and restricted availability.
Bottom line
GPT-Rosalind is a specialized OpenAI reasoning model for governed life sciences research. Its strongest reported advantages are domain focus, multi-step reasoning across biology and chemistry, support for scientific tool workflows, and performance on selected life sciences evaluations. Its main constraints are restricted access, relatively high output pricing, the need for expert validation, and missing public specifications for several important API features and limits.
For an approved research organization, it can serve as an assistant for evidence synthesis, biological analysis, drug discovery, genomics, protein work, and experiment planning. It should be treated as a supervised research system rather than an autonomous scientist or a substitute for experimental, clinical, regulatory, or safety expertise.